Efficacy and safety of ultra-high dose methylcobalamin vs placebo among patients with early-stage amyotrophic lateral sclerosis (ALS): A systematic review

Key Points

• Methylcobalamin showed improved efficacy compared to placebo in patients with early-stage amyotrophic lateral sclerosis.
• The treatment was associated with a favorable safety profile, indicating minimal adverse events during the study.
• Systematic review assessed multiple studies to evaluate the overall impact and safety of high-dose methylcobalamin.
• These findings suggest that methylcobalamin may enhance treatment options for early-stage ALS patients, highlighting the need for further research.